BIOMAT Database Logo BIOMAT Database Logo

Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma. 1978

D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.
January 1979, Cancer treatment reports,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
January 1979, Cancer treatment reports,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
cis-dichlorodiammineplatinum(II) with and without ICRF-159 in non-Hodgkin's lymphoma.
January 1980, Cancer treatment reports,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
March 1979, Cancer treatment reports,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Therapeutic potentiation of combined cis-dichlorodiammineplatinum (II) and irradiation by ICRF-159.
August 1979, International journal of radiation oncology, biology, physics,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
January 1986, Medical and pediatric oncology,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
February 1992, American journal of clinical oncology,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.
January 1980, Journal of cancer research and clinical oncology,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
January 1989, Journal of cancer research and clinical oncology,
D L Ahmann, and J H Edmonson, and S Frytak, and L K Kvols, and H F Bisel, and J Rubin
Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
July 1986, European journal of cancer & clinical oncology,
Copied contents to your clipboard!